AstraZeneca to acquire TeneoTwo Inc for $100 million
LONDON, UK: AstraZeneca has signed agreement to acquire TeneoTwo Inc., including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma. AstraZeneca will acquire all outstanding equity of TeneoTwo in exchange for…